Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT05634499
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦McGill University Health Centre - Glen Site, Montreal, Quebec, Canada
🇮🇹Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS, Meldola, Emilia-Romagna, Italy
A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-06-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT05630066
- Locations
- 🇫🇷
CHU Dijon Bourgogne Hôpital François Mitterand, Dijon, France
🇫🇷Hopital la Timone Enfants, Marseille, France
🇫🇷Groupe Hospitalier Necker Enfants Malades, Paris, France
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
- Conditions
- Childhood Idiopathic Nephrotic Syndrome
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT05627557
- Locations
- 🇫🇷
CHU de Nice, Nice, Alpes-Maritimes, France
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital - Stanford, Palo Alto, California, United States
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
- Conditions
- Small Cell Lung CancerNeuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT05619744
- Locations
- 🇺🇸
Georgetown Uni Medical Center, Washington, District of Columbia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT05614895
- Locations
- 🇺🇸
East Carolina University (ECU) Physicians - Infectious Disease Clinic - Greenville, Greenville, North Carolina, United States
🇺🇸Infectious Disease Associates, Sarasota, Florida, United States
🇰🇷Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1290
- Registration Number
- NCT05595642
- Locations
- 🇦🇷
Centro Modelo de Cardiologia, San Miguel de Tucuman, Argentina
🇧🇬Multiprofile Hospital for Active Treatment Plovdiv, Plovdiv, Bulgaria
🇩🇪Studienpraxis Berlin-Brandenburg, Berlin, Berlin, Germany
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT05583617
- Locations
- 🇦🇺
Prince of Wales Hospital, Randwick, New South Wales, Australia
🇫🇷IUCT Oncopole, Toulouse, France
🇫🇷Hopital Bretonneau, TOURS Cedex, France
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
- Conditions
- Neovascular Age-related Macular DegenerationDiabetic Macular Edema
- Interventions
- Combination Product: Faricimab PFS Configuration
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT05569148
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Retinal Consultants of Arizona, Phoenix, Arizona, United States
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
- Conditions
- Neovascular Age-related Macular DegenerationnAMD
- Interventions
- Device: PDS With Ranibizumab (100 mg/mL)
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT05562947
- Locations
- 🇨🇳
Shanghai First People's Hospital, Shanghai, China
🇨🇳Eye Hospital, Wenzhou Medical University, Wenzhou City, China
🇨🇳Xi'an People's Hospital (Xi'an Fourth Hospital), XI An, China
A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT05548556
- Locations
- 🇺🇸
University of Irvine Medical Center (UCIMC), Orange, California, United States
🇺🇸University of Kansas Medical Center, Fairway, Kansas, United States
🇺🇸Virginia Commonwealth University Medical Center, Richmond, Virginia, United States